26907-41-5

Usage

Uses

Used in Pharmaceutical Research:
CarbaMic acid, (4-bromophenyl)-, phenyl ester is used as a research compound for its potential applications in medicinal chemistry. Its unique structure and functional groups make it a valuable building block for the development of new pharmaceutical agents.
Used in Organic Synthesis:
In the field of organic synthesis, CarbaMic acid, (4-bromophenyl)-, phenyl ester is employed as a key intermediate for the synthesis of various organic compounds. Its reactivity and versatility allow for the creation of a wide range of chemical products.
Used in Drug Development:
CarbaMic acid, (4-bromophenyl)-, phenyl ester may be utilized as a potential drug candidate in the pharmaceutical industry. Its specific properties and interactions with biological targets could be harnessed to develop new therapeutic agents for various medical conditions.
Used in Chemical Modification:
CarbaMic acid, (4-broMophenyl)-, phenyl ester can be used for the chemical modification of other molecules, enhancing their properties or introducing new functionalities. This can be particularly useful in the development of advanced materials and specialty chemicals.
Note: The specific applications and uses of CarbaMic acid, (4-bromophenyl)-, phenyl ester may vary depending on the industry and the nature of the research or development being conducted. Further investigation and testing are necessary to fully understand its potential and limitations.

Upstream product

• 4005-51-0 [1,3,4]Thiadiazol-2-ylamin 
• 102-09-0 bis(phenyl) carbonate 
• 1885-14-9 phenyl chloroformate 

Downstream Products

• 1449664-97-4 4-(3-ethyl-4-(methyl(1-methyl-1H-imidazo[4,5-c]pyridin-6-yl)amino)phenyl)-N-(1,3,4-thiadiazol-5-yl)-5,6-dihydropyridine-1(2H)-carboxamide 
• 852661-43-9 1-((1R,2S,4R)-2-(((3-(4-fluorophenyl)propyl)(propyl)amino)methyl)-4-pivalamidocyclohexyl)-3-(1,3,4-thiadiazol-2-yl)urea 

Relevant academic research and scientific papers

4,5-DIHYDROISOXAZOLE DERIVATIVES AS NAMPT INHIBITORS

The present invention provides substituted 4,5-dihydroisoxazole derivatives of formula (I), which may be therapeutically useful, more particularly NAMPT inhibitors and in which R1 R2, Y, X, "Het" and "p" have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPT) in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted 4,5-dihydroisoxazole derivatives of formula (I) or a pharmaceutically acceptable salts or stereoisomers or N-oxide thereof.

IMIDAZO [4, 5 -C] PYRIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Wherein R1, L1, R3, R4, Cy, L2 and R5 are as defined herein. Novel imidazolopyridines according to Formula I, able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.

Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency

Starting with our previously described20 class of CC chemokine receptor-3 (CCR3) antagonist, we improved the potency by replacing the phenyl linker of 1 with a cyclohexyl linker and by replacing the 4-benzylpiperidine with a 3-benzylpiperidine. The resulting compound, 32, is a potent and selective antagonist of CCR3. SAR studies showed that the 3-acetylphenyl urea of 32 could be replaced with heterocyclic ureas or heterocyclic-substituted phenyl ureas and still maintain the potency (inhibition of eotaxin-induced chemotaxis) of this class of compounds in the low-picomolar range (IC50 = 10-60 pM), representing some of the most potent CCR3 antagonists reported to date. The potency of 32 for mouse CCR3 (chemotaxis IC50 = 41 nM) and its oral bioavailability in mice (20% F) were adequate to assess the efficacy in animal models of allergic airway inflammation. Oral administration of 32 reduced eosinophil recruitment into the lungs in a dose-dependent manner in these animal models. On the basis of its overall potency, selectivity, efficacy, and safety profile, the benzenesulfonate salt of 32, designated DPC168, entered phase I clinical trials.